The new class of GLP-1 weight loss drugs have been blockbusters since they arrived on the market a few years ago. These medications have made tens of billions of dollars for drugmakers and have made their way into the public consciousness in a remarkable way.
Almost three-quarters of adults in the U.S. are overweight or obese, and obesity can lead to a litany of health complications, including heart disease, joint pain, and cancer. So there’s an enormous demand for highly effective weight loss drugs like Wegovy and Zepbound.
Meeting that huge demand has been challenging. The name-brand medications are very expensive and not always covered by insurance. Even with coverage, consistent shortages of these drugs have plagued the market.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.
Already have an account? Log in
